Skip to main content

Clinical Trials Using Cisplatin

Review the clinical trials studying cisplatin on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 126-150 of 203

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Status: Active
Location: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Pembrolizumab, Cisplatin, and Rintatolimod in Treating Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Cisplatin for the Treatment of Recurrent Mucinous Ovarian Cancer, HI-MOC Study
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Radiotherapy Dose De-escalation for the Treatment of HPV-Associated Cancers of the Oropharynx
Status: Active
Location: Duke University Medical Center, Durham, North Carolina
Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Cytoreductive Surgery and Heated Cisplatin in Treating Patients with Adrenocortical Cancer
Status: Active
Location: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York
Immunotherapy (Pembrolizumab) with Chemotherapy and Chemoradiation for the Treatment of Stage II-IVb Squamous Cell Cancer of the Nasal Cavity and Paranasal Sinuses, the I-NAPA Study
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
Status: Active
Location: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Stomach Cancer with Peritoneal Metastases
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Pembrolizumab in Combination with Gemcitabine and Cisplatin for Treating Patients with High-Risk Resectable Intrahepatic Cholangiocarcinoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Cisplatin-based Hypofractionated Radiation Therapy followed by Brachytherapy in Treating Patients with Bulky or Metastatic Cervical Cancer
Status: Active
Location: University of Kentucky/Markey Cancer Center, Lexington, Kentucky
Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Gastric Cancer with Limited Peritoneal Metastasis, ROBO-CHIP Study
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Hyperthermic Intraperitoneal Chemotherapy with Cisplatin and Paclitaxel for the Treatment of Patients with Gastric and Gastroesophageal Junction Adenocarcinoma at High Risk of Peritoneal Recurrence
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
EUS-RFA PANCARDINAL-1 Trial
Status: Active
Location: The University of Texas Health Science Center, Houston, Houston, Texas
Pembrolizumab after Radiation Therapy and Chemotherapy in Treating Patients with Limited Stage Small Cell Lung Cancer
Status: Active
Location: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
Gemcitabine, Cisplatin, and Pembrolizumab before and after Surgery for the Treatment of Potentially Resectable Biliary Tract Cancer
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Tiragolumab and Atezolizumab for the Treatment Newly Diagnosed PD-L1 Positive Resectable Stage III-IV Oral Cavity Squamous Cell Carcinoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Pembrolizumab in Combination with Chemotherapy for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, SINERGY Study
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Durvalumab and Standard Chemotherapy for the Treatment of Lymph Node Positive Bladder Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsies for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial
Status: Active
Location: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Propranolol and Chemoradiation Therapy for the Treatment of Patients with Esophageal Cancer
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
Circulating Tumor DNA Monitoring for Treatment Response Prediction and Treatment Reduction after Surgery in Patients with Stage IB, II, and IIIB Non-small Cell Lung Cancer, DNA-PREDICT Trial
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida